Clinical Trial Update: Certolizumab in Recurrent Implantation Failure (RIF) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for certolizumab in recurrent implantation failure, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Unexplained Implantation Failure

Drugs mentioned

• Certolizumab (certolizumab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Recurrent Unexplained Implantation Failure | Phase 3 | Status: RECRUITING